• EZ Cap™ Firefly Luciferase mRNA: Enhanced Bioluminescent Ass

  2026-04-27

  EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure sets a new benchmark for mRNA delivery, translation efficiency, and in vivo imaging. Explore workflow optimizations, data-driven protocol parameters, and troubleshooting strategies that maximize reporter assay sensitivity with this robust, next-generation mRNA reagent.

• Applied Workflows with EZ Cap™ Cy5 EGFP mRNA (5-moUTP)

  2026-04-27

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) empowers researchers to simultaneously track mRNA delivery and translation efficiency with dual fluorescence, Cap 1 capping, and immune-evasive nucleotide modifications. Learn how to optimize gene regulation assays, troubleshoot delivery bottlenecks, and leverage machine learning–driven nanoparticle innovations for reproducible, quantitative results.

• SEMA3E Drives Beige Adipocyte Thermogenesis via β-Catenin Pa

  2026-04-26

  This study uncovers the regulatory role of SEMA3E in promoting beige adipocyte differentiation and thermogenesis by modulating β-catenin signaling in mice. The findings provide mechanistic insight into adipose tissue plasticity and metabolic regulation, offering new perspectives for inflammation and lipid metabolism research.

• Firefly Luciferase mRNA: Optimizing 5-moUTP-Based Reporter W

  2026-04-25

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) empowers highly sensitive, reproducible bioluminescent reporter assays and mRNA delivery validation. Its advanced 5-moUTP and Cap 1 modifications yield robust expression, innate immune suppression, and workflow flexibility—key for translation efficiency studies and in vivo imaging.

• Neutrophil NETs Drive Brain Injury via cGAS-STING Activation

  2026-04-24

  This study reveals that neutrophil extracellular traps (NETs) exacerbate surgical brain injury (SBI) by activating the cGAS-STING pathway, leading to heightened neuroinflammation and neuronal damage. Inhibiting NETs or cGAS-STING signaling mitigated injury, highlighting new therapeutic directions for SBI and offering mechanistic insight for translational research.

• TMRE Mitochondrial Membrane Potential Assay Kit: Mechanisms,

  2026-04-24

  Explore the scientific foundations and advanced applications of the TMRE mitochondrial membrane potential assay kit. This article uniquely integrates mechanistic insights from NECSO research, providing a deeper understanding for mitochondrial function analysis and apoptosis detection.

• TCAIM Modulates Mitochondrial Metabolism via OGDH Regulation

  2026-04-23

  Wang et al. (2025) identify the mitochondrial DNAJC co-chaperone TCAIM as a specific regulator of the α-ketoglutarate dehydrogenase (OGDH) protein, revealing a novel post-translational mechanism for metabolic control. This work has significant implications for understanding mitochondrial proteostasis and its effects on cellular energy production.

• Optimizing Neuroprotection Assays with IEM 1460 (SKU B6811)

  2026-04-23

  Discover how IEM 1460 (SKU B6811) addresses key lab challenges in AMPA receptor inhibition, neuroprotection, and synaptic transmission research. This guide provides scenario-driven, evidence-backed strategies for reliable data and assay reproducibility, positioning IEM 1460 as a trusted solution for neuroscience workflows.

• Biomimetic Chromatography for Modeling Pulmonary Drug Permea

  2026-04-22

  This study benchmarks biomimetic open tubular capillary electrochromatography and immobilised artificial membrane chromatography, both coupled with mass spectrometry, for predicting the lung permeability of pharmaceuticals. The findings provide a robust analytical platform for high-throughput screening in respiratory drug development, informing the selection and optimization of anti-inflammatory corticosteroids such as Budesonide.

• Hypoxia and Immunometabolism: Mechanisms in Tumor Microenvir

  2026-04-22

  This review synthesizes recent insights into how hypoxia-driven metabolic reprogramming and immunometabolism shape the tumor microenvironment (TME), emphasizing the mechanisms of immune evasion and metabolic competition. The findings highlight the importance of glucose metabolism in tumor progression and immunosuppressive niche formation, with implications for developing targeted therapies.

• Transmission Dynamics of Carbapenemase Genes in CREC in Guan

  2026-04-21

  This study systematically investigates the prevalence, genetic context, and transmission mechanisms of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) across eight teaching hospitals in Guangdong, China, during the COVID-19 pandemic. By revealing high rates of multidrug resistance and efficient gene transfer, the work delivers critical insights for researchers developing resistance surveillance and experimental protocols.

• ATRX Loss Sensitizes High-Grade Glioma to RTK/PDGFR Inhibito

  2026-04-21

  This study identifies that ATRX-deficient high-grade glioma cells exhibit increased sensitivity to receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors. These findings provide a rationale for stratifying glioma patients by ATRX status in clinical trials of multi-targeted kinase inhibitors and inform precision therapeutic strategies.

• Diphenyleneiodonium Chloride: Applied Redox and cAMP Modulat

  2026-04-20

  Diphenyleneiodonium chloride (DPI) stands out as a gold-standard probe for dissecting redox enzyme function and cAMP signaling, empowering advanced research in oxidative stress and cell signaling. This article integrates recent breakthroughs on Nrf2 pathway regulation with actionable workflow guidance, troubleshooting, and comparative insights to maximize experimental reproducibility.

• MVC Triggers RhoA/ROCK1 Pathway to Disrupt Tight Junctions

  2026-04-20

  This study elucidates how the Minute Virus of Canines (MVC) directly engages the RhoA/ROCK1/MLC2 signaling axis to disrupt epithelial tight junctions, facilitating occludin-mediated viral entry. The identification of VP2-ROCK1 interaction and pathway dependency advances our understanding of viral pathogenesis and highlights potential molecular targets for antiviral intervention.

• DOT1L Inhibition Enhances Lenalidomide Response in Myeloma

  2026-04-19

  This study reveals that inhibiting DOT1L, a histone H3K79 methyltransferase, reprograms innate immunity and amplifies the anti-myeloma activity of immunomodulatory drugs such as lenalidomide. Mechanistic insights demonstrate epigenetic-immune crosstalk and highlight a new avenue for improving multiple myeloma therapies.

15601 records 1/1041 page Next 12345 下5页 Last page